10x Genomics(US:TXG) ZACKSยท2025-10-30 15:07Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for 10x Genomics despite lower revenues, with a focus on how actual results will compare to estimates [1][2]. Earnings Expectations - 10x Genomics is expected to report a quarterly loss of $0.27 per share, reflecting a year-over-year change of +10% [3]. - Revenue is projected to be $142.39 million, down 6.1% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 1.46% higher in the last 30 days, indicating a positive reassessment by analysts [4]. - The Most Accurate Estimate for 10x Genomics is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +11.39% [12]. Earnings Surprise Prediction - A positive Earnings ESP reading suggests a likely earnings beat, especially when combined with a Zacks Rank of 1 [10]. - 10x Genomics currently holds a Zacks Rank of 1, indicating strong potential for beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, 10x Genomics was expected to post a loss of $0.35 per share but instead reported earnings of $0.28, resulting in a surprise of +180% [13]. - Over the past four quarters, the company has exceeded consensus EPS estimates three times [14]. Industry Context - In the Zacks Medical Info Systems industry, Nyxoah SA is expected to report a loss of $0.61 per share, indicating a year-over-year change of -10.9% [18]. - Nyxoah's revenue is expected to be $1.95 million, up 40.3% from the previous year [18]. - Despite a higher Most Accurate Estimate leading to an Earnings ESP of +19.67%, Nyxoah's Zacks Rank of 4 (Sell) complicates predictions for an earnings beat [19].